Evan Anderson, CEO & Board Member, Luma Therapeutics
Evan Anderson, CEO and Board Member of Luma Therapeutics, has 17 years of experience in early stage product and market development. He completed the Stanford Biodesign Fellowship in 2004 and was first manager of R&D and then distribution sales at Spiracur (acquired by Acelity).
From the Luma Therapeutics website:
We are a medical device company developing light therapies for the 40 million people in the US with inflammatory skin disorders. Luma Therapeutics was born when our CEO Evan Anderson found that he had psoriasis and discovered a way to treat himself effectively. He knew then that he wanted to develop similar treatments for the millions of other people suffering from skin disorders.
We work hard every day to help people get clear skin with easy to use, affordable therapies.
Our goal is to develop an at home treatment that will put psoriasis in remission for an extended period of time after only a few weeks of therapy.
Craig Mermel: Selling Science Fiction
Daniel Etra: Scaling the Right Level of Care
Peter Socarras: A Connection to Purpose
Joanna Drake: Investing in Care
Sandeep Akkaraju: Simplifying Care in the Modern World
Riddhiman Das: Delivering Breakthrough Innovations Using Secure Data
Yasi Baiani: Optimizing Healthcare Integration
Deborah Kilpatrick: Improving Everyday Health
Zack Gray: The Opioid Crises Treatment Gap
Patricia Bradley: The Full Continuum of Care
Alon Joffe: Bridging the Patient-Clinician Gap in Behavioral Health
A. J. Loiacono: The Tylenol Rule
Erin Harkless Moore: Underrepresented & Undercapitalized
David Hanson: The Future of AI
Richard Lungen: Looking Behind the Scenes
Ogi Kavazovic: A Broken System
Sean Saint: Standalone Success
David Mou: Telehealth Mental Revolution
Brad Hirsch: Revolutionizing Clinical Trials
Tamar Thompson: Coding Toward a Better Health-Policy Future
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
NABOR® TALKS
U.S Property Podcast
Aligned Money Show
The Ramsey Show
Planet Money